Tekla Capital Management
Boston, Massachusetts, United StatesFounded 1986
Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts, acting as the investment adviser for four closed-end funds that invest predominantly in public and private healthcare companies. Its advisory business was acquired by abrdn Inc. in October 2023.
57% of their portfolio is in Biotech & Life Sciences. They made 1 investment in the last 12 months. Average disclosed round size is $90.7M (across 29 rounds with reported amounts).
Portfolio
31
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Team
CR
Christian Richard
Partner
CA
Chris Abbott
Investment Director
DO
Daniel Omstead
CEO
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
35 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ovid Therapeutics Inc. | Series B | $60M | Mar 2026 |
 Invetx | Series B | $86M | Jan 2022 |
 Quell Therapeutics | Series B | $156M | Nov 2021 |
 Quell | Unknown | $156M | Nov 2021 |
 Arbor Biotechnologies | Series B | $215M | Nov 2021 |
 BioTheryX | Series E | $92M | May 2021 |
 HiberCell | Series B | $67.4M | May 2021 |
 ReCode Therapeutics | Series B | $50M | Jan 2021 |
| Quell Therapeutics | Series B | $156M | Jan 2021 |
 Arbor Biotechnologies | Series B | $215M | Jan 2021 |
| RReCode | Series B | $50M | Jan 2021 |
| PPriothera Ltd. | Series A | — | Oct 2020 |
 HotSpot Therapeutics | Series B | $65M | May 2020 |
 Arkuda Therapeutics | Series A | $44M | Nov 2019 |
| AAmphivena Therapeutics | Series C | $62M | Sep 2019 |
 Amphivena | Series C | $62M | Sep 2019 |
 Galera | Series C | — | Sep 2018 |
 Galera Therapeutics | Series C | $150M | Sep 2018 |
| TTherachon | Debt | — | Aug 2018 |
 Sutro Biopharma | Series E | $85.4M | Jul 2018 |
| SSutro Bio | Series E | $85.4M | Jul 2018 |
 Sutro | Series E | $85.4M | Jul 2018 |
| CCurasen | Series A | $54.5M | Jan 2018 |
 Atreca | Series C | $125M | Jan 2018 |
 Milestone Pharmaceuticals | Series C | $55M | Aug 2017 |
Page 1 of 2
Top Co-Investors
Pfizer Ventures7 shared
Surveyor Capital7 shared
SV Health Investors7 shared
Sofinnova Partners6 shared
Ridgeback Capital6 shared
Amgen Ventures6 shared
Alta Partners6 shared
Novo Capital6 shared
Rock Springs Capital6 shared
Cormorant Asset Management5 shared
AJU IB Investment5 shared
Samsara BioCapital5 shared
Novartis Venture Fund5 shared
ARCH Venture Partners4 shared
MPM Capital4 shared
Adage Capital Management4 shared
Celgene4 shared
Eventide Asset Management4 shared
Pappas Capital4 shared
Solasta Ventures3 shared
Last updated: 20 October 2026